Giuseppe
Emeritus
JAMA -- Abstract: Antiretroviral Treatment of Adult HIV Infection: 2010 Recommendations of the International AIDS Society-USA Panel (JAMA, abstract, edited)
[Source: JAMA, original abstract and link to free full text, <cite cite="http://jama.ama-assn.org/cgi/content/short/304/3/321">JAMA -- Abstract: Antiretroviral Treatment of Adult HIV Infection: 2010 Recommendations of the International AIDS Society-USA Panel, July 21, 2010, Thompson et al. 304 (3): 321</cite>. Edited.]
Vol. 304 No. 3, July 21, 2010
CLINICIAN'S CORNER
Antiretroviral Treatment of Adult HIV Infection2010 - Recommendations of the International AIDS Society?USA Panel
Melanie A. Thompson, MD; Judith A. Aberg, MD; Pedro Cahn, MD; Julio S. G. Montaner, MD; Giuliano Rizzardini, MD; Amalio Telenti, MD, PhD; Jos? M. Gatell, MD, PhD; Huldrych F. G?nthard, MD; Scott M. Hammer, MD; Martin S. Hirsch, MD; Donna M. Jacobsen, BS; Peter Reiss, MD, PhD; Douglas D. Richman, MD; Paul A. Volberding, MD; Patrick Yeni, MD; Robert T. Schooley, MD
JAMA. 2010;304(3):321-333. doi:10.1001/jama.2010.1004
Context
Recent data regarding the consequences of untreated human immunodeficiency virus (HIV) infection and the expansion of treatment choices for antiretroviral-naive and antiretroviral-experienced patients warrant an update of the International AIDS Society?USA guidelines for the use of antiretroviral therapy in adults with HIV infection.
Objectives
To provide updated recommendations for management of HIV-infected adults, using antiretroviral drugs and laboratory monitoring tools available in the international, developed-world setting. This report provides guidelines for when to initiate antiretroviral therapy, selection of appropriate initial regimens, patient monitoring, when to change therapy, and what regimens to use when changing.
Data Sources and Study Selection
A panel with expertise in HIV research and clinical care reviewed relevant data published or presented at selected scientific conferences since the last panel report through April 2010. Data were identified through a PubMed search, review of scientific conference abstracts, and requests to antiretroviral drug manufacturers for updated clinical trials and adverse event data.
Data Extraction and Synthesis
New evidence was reviewed by the panel. Recommendations were drafted by section writing committees and reviewed and edited by the entire panel. The quality and strength of the evidence were rated and recommendations were made by full panel consensus.
Conclusions
Patient readiness for treatment should be confirmed before initiation of antiretroviral treatment. Therapy is recommended for asymptomatic patients with a CD4 cell count ≤500/?L, for all symptomatic patients, and those with specific conditions and comorbidities. Therapy should be considered for asymptomatic patients with CD4 cell count >500/?L. Components of the initial and subsequent regimens must be individualized, particularly in the context of concurrent conditions. Patients receiving antiretroviral treatment should be monitored regularly; treatment failure should be detected and managed early, with the goal of therapy, even in heavily pretreated patients, being HIV-1 RNA suppression below commercially available assay quantification limits.
Author Affiliations:
AIDS Research Consortium of Atlanta, Atlanta, Georgia (Dr Thompson); University of California San Diego, La Jolla (Dr Schooley); New York University School of Medicine, New York (Dr Aberg); Hospital Juan Fernandez/University of Buenos Aires Medical School and Fundacion Huesped, Argentina (Dr Cahn); Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain (Dr Gatell); University Hospital Zurich, Division of Infectious Diseases and Hospital Epidemiology, University of Zurich, Zurich, Switzerland (Dr G?nthard); Columbia University College of Physicians and Surgeons, New York, New York (Dr Hammer); Harvard Medical School, Boston, Massachusetts (Dr Hirsch); International AIDS Society?USA, San Francisco, California (Ms Jacobsen); BC-Centre for Excellence in HIV/AIDS, Providence Health Care and University of British Columbia, Vancouver, Canada (Dr Montaner); Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands (Dr Reiss); University of California San Diego and Veterans Affairs San Diego Healthcare System (Dr Richman); Luigi Sacco Hospital, Milan, Italy (Dr Rizzardini); University Hospital of Lausanne, Lausanne, Switzerland (Dr Telenti); University of California San Francisco and San Francisco Veterans Affairs Medical Center (Dr Volberding); and H?pital Bichat-Claude Bernard and Xavier Bichat Medical School, Paris, France (Dr Yeni).
-
-----
[Source: JAMA, original abstract and link to free full text, <cite cite="http://jama.ama-assn.org/cgi/content/short/304/3/321">JAMA -- Abstract: Antiretroviral Treatment of Adult HIV Infection: 2010 Recommendations of the International AIDS Society-USA Panel, July 21, 2010, Thompson et al. 304 (3): 321</cite>. Edited.]
Vol. 304 No. 3, July 21, 2010
CLINICIAN'S CORNER
Antiretroviral Treatment of Adult HIV Infection2010 - Recommendations of the International AIDS Society?USA Panel
Melanie A. Thompson, MD; Judith A. Aberg, MD; Pedro Cahn, MD; Julio S. G. Montaner, MD; Giuliano Rizzardini, MD; Amalio Telenti, MD, PhD; Jos? M. Gatell, MD, PhD; Huldrych F. G?nthard, MD; Scott M. Hammer, MD; Martin S. Hirsch, MD; Donna M. Jacobsen, BS; Peter Reiss, MD, PhD; Douglas D. Richman, MD; Paul A. Volberding, MD; Patrick Yeni, MD; Robert T. Schooley, MD
JAMA. 2010;304(3):321-333. doi:10.1001/jama.2010.1004
Context
Recent data regarding the consequences of untreated human immunodeficiency virus (HIV) infection and the expansion of treatment choices for antiretroviral-naive and antiretroviral-experienced patients warrant an update of the International AIDS Society?USA guidelines for the use of antiretroviral therapy in adults with HIV infection.
Objectives
To provide updated recommendations for management of HIV-infected adults, using antiretroviral drugs and laboratory monitoring tools available in the international, developed-world setting. This report provides guidelines for when to initiate antiretroviral therapy, selection of appropriate initial regimens, patient monitoring, when to change therapy, and what regimens to use when changing.
Data Sources and Study Selection
A panel with expertise in HIV research and clinical care reviewed relevant data published or presented at selected scientific conferences since the last panel report through April 2010. Data were identified through a PubMed search, review of scientific conference abstracts, and requests to antiretroviral drug manufacturers for updated clinical trials and adverse event data.
Data Extraction and Synthesis
New evidence was reviewed by the panel. Recommendations were drafted by section writing committees and reviewed and edited by the entire panel. The quality and strength of the evidence were rated and recommendations were made by full panel consensus.
Conclusions
Patient readiness for treatment should be confirmed before initiation of antiretroviral treatment. Therapy is recommended for asymptomatic patients with a CD4 cell count ≤500/?L, for all symptomatic patients, and those with specific conditions and comorbidities. Therapy should be considered for asymptomatic patients with CD4 cell count >500/?L. Components of the initial and subsequent regimens must be individualized, particularly in the context of concurrent conditions. Patients receiving antiretroviral treatment should be monitored regularly; treatment failure should be detected and managed early, with the goal of therapy, even in heavily pretreated patients, being HIV-1 RNA suppression below commercially available assay quantification limits.
Author Affiliations:
AIDS Research Consortium of Atlanta, Atlanta, Georgia (Dr Thompson); University of California San Diego, La Jolla (Dr Schooley); New York University School of Medicine, New York (Dr Aberg); Hospital Juan Fernandez/University of Buenos Aires Medical School and Fundacion Huesped, Argentina (Dr Cahn); Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain (Dr Gatell); University Hospital Zurich, Division of Infectious Diseases and Hospital Epidemiology, University of Zurich, Zurich, Switzerland (Dr G?nthard); Columbia University College of Physicians and Surgeons, New York, New York (Dr Hammer); Harvard Medical School, Boston, Massachusetts (Dr Hirsch); International AIDS Society?USA, San Francisco, California (Ms Jacobsen); BC-Centre for Excellence in HIV/AIDS, Providence Health Care and University of British Columbia, Vancouver, Canada (Dr Montaner); Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands (Dr Reiss); University of California San Diego and Veterans Affairs San Diego Healthcare System (Dr Richman); Luigi Sacco Hospital, Milan, Italy (Dr Rizzardini); University Hospital of Lausanne, Lausanne, Switzerland (Dr Telenti); University of California San Francisco and San Francisco Veterans Affairs Medical Center (Dr Volberding); and H?pital Bichat-Claude Bernard and Xavier Bichat Medical School, Paris, France (Dr Yeni).
-
-----